menu
    • menu
    [{"orgOrder":0,"company":"Nocion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Taplucainium","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Nocion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nocion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nocion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nocion Therapeutics","sponsor":"Arkin Bio Capital | Monograph Capital | BioInnovation Capital | Canaan Partners | F-Prime Capital","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2026","type":"Series B Financing","leadProduct":"Taplucainium","moa":"Sodium channels","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Nocion Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.089999999999999997,"dosageForm":"Inhalation","sponsorNew":"Nocion Therapeutics \/ Arkin Bio Capital | Monograph Capital | BioInnovation Capital | Canaan Partners | F-Prime Capital","highestDevelopmentStatusID":"8","companyTruncated":"Nocion Therapeutics \/ Arkin Bio Capital | Monograph Capital | BioInnovation Capital | Canaan Partners | F-Prime Capital"}]

    Find Clinical Drug Pipeline Developments & Deals for Taplucainium

    Menu

    Taplucainium

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nocion Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Nocion Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Taplucainium

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Arkin Bio Capital | Monograph Capital | BioInnovation Capital | Canaan Partners | F-Prime Capital

                            Deal Size : $93.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Nocion Therapeutics Boosts Series B to $93M for Taplucainium in Chronic Cough Development

                            Details : Series B financing for Taplucainium, a miscellaneous product targeting sodium channels, to address refractory chronic cough.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 07, 2026

                            Lead Product(s) : Taplucainium

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Arkin Bio Capital | Monograph Capital | BioInnovation Capital | Canaan Partners | F-Prime Capital

                            Deal Size : $93.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nocion Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Nocion Therapeutics

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Taplucainium

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nocion Therapeutics Announces First Patient Dosed in ASPIRE Phase 2b Chronic Cough Study

                            Details : NOC-110 (taplucainium) is a proprietary molecule in the novel class of charged sodium channel blockers, being investigated for the treatment of chronic cough.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 18, 2024

                            Lead Product(s) : Taplucainium

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.